Churchill Downs Calls for FTC Investigation into HISA Amid Albuterol Violations

Churchill Downs Incorporated has escalated tensions with the Horseracing Integrity and Safety Authority (HISA) by petitioning the Federal Trade Commission (FTC) for an independent review of HISA's operations. This move comes on the heels of HISA's provisional suspension of trainer Angel Quiroz, who is facing allegations surrounding medication and horse welfare violations.

In a letter dated August 28, addressed to FTC Chairman Andrew Ferguson and Commissioner Mark Meador, Churchill Downs articulated its concerns regarding HISA's governance, expressing doubts over transparency, technological safeguards, and accountability within the organization. The company has requested that the FTC initiate a formal investigation into several critical aspects, including racing integrity, the protection of sensitive information, and data security measures within the industry.

Quiroz's Suspension and Allegations

HISA's scrutiny intensified recently following a series of violations attributed to Quiroz, culminating in an enforcement action on August 31, which cited violations of Rules 2215 and 2221. Quiroz's registration was provisionally suspended effective September 1, pending a hearing. The authority claims to have "clear and convincing evidence" indicating that Quiroz's actions posed an immediate risk to the horses under his care.

Specifically, three horses—Bonita Rough, Scootaloo, and Tepeyac—associated with Quiroz allegedly tested positive for Albuterol, a banned substance unless prescribed under specific conditions. The gravity of the situation is underscored by the potential penalties surrounding anti-doping violations, which could include a two-year suspension and a fine of up to $25,000 for each incident.

Details of the Allegations

The investigation details surrounding Bonita Rough surfaced after a blood sample taken during a workout at the Fair Hill Training Center on July 10 tested positive for Albuterol. Despite claims from Quiroz that he obtained the medication through a veterinarian, HISA's records revealed no legitimate authorization for its use on the horse.

Quiroz allegedly informed investigators that he nebulized Bonita Rough with Albuterol sourced from the veterinarian at Gulfstream, claiming it was permissible to use it on the horse despite its prescription for another. This admission has raised red flags for HISA, particularly as no documentation for such a treatment appears in the regulatory portal.

HISA alleges that Quiroz continued to administer medications without proper oversight, as evidenced by further positive tests from Scootaloo and Tepeyac following his initial notification regarding Bonita Rough. These multiple violations led HISA to assert that Quiroz's actions were indicative of a serious threat to both the horses and the riders involved.

Broader Questions About HISA's Governance

This incident has prompted Churchill Downs to not only address the individual allegations against Quiroz but also to question the overall governance of HISA. The company cites a concerning episode involving horse racing data analyst Marshall Gramm, who was charged with multiple rule violations related to unauthorized access to confidential veterinary information.

The controversy surrounding Gramm’s access to sensitive health information is symptomatic of larger systemic issues within HISA. Churchill Downs pointed out that the very nature of this information should have been tightly controlled, raising alarm bells over the integrity of the HISA Portal.

Through its letter to the FTC, Churchill Downs does not seek to absolve Gramm of responsibility but rather emphasizes that the real challenge lies in understanding how such access was possible in the first place. The company’s focus on transparency highlights the need for HISA to publicly acknowledge and rectify its governance and operational weaknesses.

Concerns and Calls for Reform

Churchill Downs has called for a thorough review of HISA beyond the specific allegations involving Quiroz and Gramm. The requested investigation would encompass the overall credibility of the Fair Hill Five controversy, timing and disclosures related to any banned substance positives, and exploration of HISA's relationships with technology providers.

Key questions remain about HISA's procurement processes, vendor oversight, and the adequacy of its information security governance, especially given its role as a regulator with federally authorized powers. The company insists that HISA's legitimacy hinges on its ability to present itself as transparent, accountable, and technologically proficient.

Going further, Churchill Downs asserts that if HISA desires to rebuild trust within the industry, it must undertake a comprehensive accounting of its failures, understand their root causes, and ensure that such incidents are not repeated in the future.

Meanwhile, HISA continues to maintain that it is enhancing its technological frameworks to prevent unauthorized access, stating that it will impose significant consequences on individuals who compromise the integrity of racing regulations.

Ultimately, the fallout from these developments indicates a critical period of reassessment for both HISA and industry stakeholders, as parties navigate the aftermath of heightened scrutiny and the demand for improved standards of accountability.